Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 4
2004 2
2005 2
2006 3
2007 8
2008 8
2009 7
2010 4
2011 7
2012 5
2013 5
2014 5
2015 4
2016 4
2018 3
2019 2
2020 4
2021 5
2022 5
2023 5
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
Sims JR, Zimmer JA, Evans CD, Lu M, Ardayfio P, Sparks J, Wessels AM, Shcherbinin S, Wang H, Monkul Nery ES, Collins EC, Solomon P, Salloway S, Apostolova LG, Hansson O, Ritchie C, Brooks DA, Mintun M, Skovronsky DM; TRAILBLAZER-ALZ 2 Investigators. Sims JR, et al. JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239. JAMA. 2023. PMID: 37459141 Free PMC article.
Atogepant for the Preventive Treatment of Migraine.
Ailani J, Lipton RB, Goadsby PJ, Guo H, Miceli R, Severt L, Finnegan M, Trugman JM; ADVANCE Study Group. Ailani J, et al. N Engl J Med. 2021 Aug 19;385(8):695-706. doi: 10.1056/NEJMoa2035908. N Engl J Med. 2021. PMID: 34407343 Clinical Trial.
Antibiofilm polysaccharides.
Rendueles O, Kaplan JB, Ghigo JM. Rendueles O, et al. Among authors: kaplan jb. Environ Microbiol. 2013 Feb;15(2):334-46. doi: 10.1111/j.1462-2920.2012.02810.x. Epub 2012 Jun 26. Environ Microbiol. 2013. PMID: 22730907 Free PMC article. Review.
Antibiotic-induced biofilm formation.
Kaplan JB. Kaplan JB. Int J Artif Organs. 2011 Sep;34(9):737-51. doi: 10.5301/ijao.5000027. Int J Artif Organs. 2011. PMID: 22094552 Review.
Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.
Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. Foley JF, et al. Lancet Neurol. 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. Lancet Neurol. 2022. PMID: 35483387 Clinical Trial.
Biofilm matrix-degrading enzymes.
Kaplan JB. Kaplan JB. Methods Mol Biol. 2014;1147:203-13. doi: 10.1007/978-1-4939-0467-9_14. Methods Mol Biol. 2014. PMID: 24664835
Ensuring remote diagnostics for pathologists: an open letter to the US Congress.
Lennerz JK, Pantanowitz L, Amin MB, Eltoum IE, Hameed MR, Kalof AN, Khanafshar E, Kunju LP, Lazenby AJ, Montone KT, Otis CN, Reid MD, Staats PN, Whitney-Miller CL, Abendroth CS, Aron M, Birdsong GG, Bleiweiss IJ, Bronner MP, Chapman J, Cipriani NA, de la Roza G, Esposito MJ, Fadare O, Ferrer K, Fletcher CD, Frishberg DP, Garcia FU, Geldenhuys L, Gill RM, Gui D, Halat S, Hameed O, Hornick JL, Huber AR, Jain D, Jhala N, Jorda M, Jorns JM, Kaplan J, Khalifa MA, Khan A, Kim GE, Lee EY, LiVolsi VA, Longacre T, Magi-Galluzzi C, McCall SJ, McPhaul L, Mehta V, Merzianu M, Miller SB, Molberg KH, Moreira AL, Naini BV, Nosé V, O'Toole K, Picken M, Prieto VG, Pullman JM, Quick CM, Reynolds JP, Rosenberg AE, Schnitt SJ, Schwartz MR, Sekosan M, Smith MT, Sohani A, Stowman A, Vanguri VK, Wang B, Watts JC, Wei S, Whitney K, Younes M, Zee S, Bracamonte ER. Lennerz JK, et al. Among authors: kaplan j. Nat Med. 2022 Dec;28(12):2453-2455. doi: 10.1038/s41591-022-02040-6. Nat Med. 2022. PMID: 36266514 No abstract available.
Multidisciplinary management for esophageal and gastric cancer.
Boniface MM, Wani SB, Schefter TE, Koo PJ, Meguid C, Leong S, Kaplan JB, Wingrove LJ, McCarter MD. Boniface MM, et al. Among authors: kaplan jb. Cancer Manag Res. 2016 Apr 22;8:39-44. doi: 10.2147/CMAR.S101169. eCollection 2016. Cancer Manag Res. 2016. PMID: 27217796 Free PMC article. Review.
Intracerebral haemorrhage during alemtuzumab administration.
Azevedo CJ, Kutz C, Dix A, Boster A, Sanossian N, Kaplan J. Azevedo CJ, et al. Among authors: kaplan j. Lancet Neurol. 2019 Apr;18(4):329-331. doi: 10.1016/S1474-4422(19)30076-6. Epub 2019 Feb 15. Lancet Neurol. 2019. PMID: 30777657 No abstract available.
86 results